Prevalence and Antifungal Susceptibility Profile of Cryptococcus neoformance among Pregnant Women in Abakaliki, Ebonyi State, Nigeria
DOI:
https://doi.org/10.51412/psnnjp.2024.17Abstract
Background: The prevalence and antifungal susceptibility profile of Cryptococccus neoformans was investigated among pregnant women hospitalized in a tertiary Hospital in Abakaliki, Ebonyi State capital.
Methods: A total of (50) pregnant women were enrolled in the study and a subsequent 50 urine samples were cultured on Sabouraud dextrose agar (SDA). Culture plates which showed significant growth were further processed for the identification of Cryptococcus using standard microbiology procedures. Antifungal agents with known potency were used to determine susceptibility profile of the isolates according to Kirby-Bauer disc diffusion method.
Results: The prevalence of isolation was 12% and the drug of choice was found to be amphotericin B (83% susceptibility). Isolates were resistant to nystatin (%) followed by voriconazole (%). The prevalence of C. neoformance among pregnant women in relation to age and trimester revealed that the observed changes are likely to have occurred by chance at α = 0.0.5 (N=6).
Conclusion: Effective screening of pregnant women for neglected invasive fungal diseases should be considered an additional step in ensuring safe maternal and child health care.
References
Bahn YS, Sun S, Heitman J and Lin X (2020) Microbe profile: Cryptococcus neoformans species complex. Microbiology 166 (9): 797-799.
Costa MLB, Souza JPD, Olivera AFD and Pinto JL (2009) Cryptococcal meningitis in HIVnegative pregnant women: Case report and review of literature” Revista do Instituto de Medicina Tropical de São Paulo 51(5): 289-294
Sabiiti W and May RC (2012) Mechanism of infection by the human fungal pathogen Cryptococcus neoformans. Future Microbiology 7: 1297-1313.
Levitz SM (1991) The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Reviews of Infectious Diseases 13: 1163-1169
Caroline C, Anamelia LB and Arturo C (2014) The tools for virulence of Cryptococcus neoformans. Advances in Applied Microbiolog 87: 1-41.
Anjum S and Williamson PR (2019) Clinical aspect of immune damage in Ccrptococcosis. Current Fungal Infection Reports 13: 99-108.
Youbao Z, Leixin Y and Lingi W (2023) Cryptococcus neoformanas, a global threat to human health. Infectious Diseases of Poverty 20:9-11.
Singh N and Perfect JR (2007) Immune constitution Syndromes and exacerbation of infections after pregnancy. Clinical Infectious Diseases 45(9): 1192-1199.
Sinbanda EL, Weller IV, Hakim JG and CowanFM (2013) The magnitude of loss to follow-up on HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of case: ASystemic Review and meta-analysis.AIDS 27:2787-2797.
Rajasingham R, Smith RM, Park BJ (2017) Global burden of disease of HIV-associated Cryptococcus meningitis: an update analysis. Lancet infectious Diseases 17: 873-881.
Maria LB, Joae PD and Joao LP (2009) Crytococcal meningitis in HIV negative pregnant women: case report and Review of Literature. Revista do Instituto de Medicina Tropical de São Paulo 51(5):289-94.
Bicanic T and Harrison TS (2005) Cryptococcal meningitis. British Medical Bulletin 72:99-118.
Deorukhkar SC, Saini S and Jadhov P (2012). Evaluation of different media for germ tube production of Candida albicans and Candida dubliniensis. International Journal of Biomedical Advanced Research 3: 704-707.
Moyrand F and Janbon G (2004) UGDi, encoding the Cryptococcus neoformanssUDP-glucoseo dehydrogenase, is essential for growth at 37 C and for capsule biosynthesis. Eucharyot Cell 3:1601-1608.
Macfaddin JF (2000) Urease Test. Biochemical Test for identification of medical Bacteria. (3Ed.). Philadelphia: Lippincott Williams and Wilkins, USA, pp424-438.
Deorukhkar SC and Roushani S (2018) Identification of Candida species: conventional methods in the era of molecular diagnosis. Annals of Microbiology and Immunology 1(1): 1-6.
Ochie J and Kolhatkar A (2000) Textbook of medical Laboratory Science Theory and Practical: 2ndedition. Tata McGraw – Hill. 331-349.
Perfect JR, Dismukes WE, Dromer F, Goldman DL, John RG (2010) Clinical practice Guidelines for the management of Cryptococcal Disease. Uptake by the infectious Diseases Society of America. Clinical Infections Diseases 50(3): 291-322.
Perfect JR and Cox GM (1999) Drug resistance in Cryptococcus neoformans. Indian Journal Pathology 2(4): 259-269.
Lagrou K, Eldere J, Hagen F and Keulees S (2000) Zoonotic transmission of Cryptococcus neoformans from amagpietoan immunocompetent patient. Journal of Internal Medicine 257:380-388
Rajasingham R, Govender NP, Jordan A, Loyse A (2020) The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infectious Disease 15(6): 789-794
Philpot CR and Lo D (1972) Cryptococcus meningitis in pregnancy. Medical journal of Australia 2(18): 1005-1007.
Mar G and Gardenas I (2010) The immune system in pregnancy: a unique complexity” American Journal of Reproductive Immunology 63(6): 425-433
Akaihe CL and Nweze EL (2021) Epidemiology of Cryptococcosis in West Africa. Mycosis 64(1): 4-17
Food and drug administration (FDA) U.S.A (2011) Use of long term, high-dose diflucan (fluconazole) during pregnancy may be associated with birth defect in infants.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Nigerian Journal of Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
